
	Calithera Biosciences, Inc. is a clinical-stage company focused on the discovery, development and commercialization of first-in-class small molecule oncology therapeutics.&nbsp; The company is building a pipeline of targeted anti-cancer compounds that inhibit pathways critical to tumor growth and survival.&nbsp; Calithera&#39;s lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is currently being tested in patients with advanced solid and hematological cancers.&nbsp; Calithera Biosciences is headquartered in South San Francisco.
